Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial-Reference-Cited by-同舟云学术

Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial

Published:2016-08-22 Issue:4 Volume:58 Page:816-821
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Song Zheng,Wang Huaqing,Zhang Huilai,Zhao Kuo,Zhang Man,Yang Fang

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1213838

Reference20 articles.

1. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

2. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

3. The Changeable Nature of Patients' Fears Regarding Chemotherapy

4. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

5. Management of highly emetogenic chemotherapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16

2. Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting;Medicine;2020-08-14

3. Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2019-11-21

4. Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan;In Vivo;2019

5. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis;The Oncologist;2018-01-12